1598 related articles for article (PubMed ID: 27455225)
21. The role of epithelial-mesenchymal transition-regulating transcription factors in anti-cancer drug resistance.
Seo J; Ha J; Kang E; Cho S
Arch Pharm Res; 2021 Mar; 44(3):281-292. PubMed ID: 33768509
[TBL] [Abstract][Full Text] [Related]
22. Epigenetic Regulation of Inflammatory Cytokine-Induced Epithelial-To-Mesenchymal Cell Transition and Cancer Stem Cell Generation.
Markopoulos GS; Roupakia E; Marcu KB; Kolettas E
Cells; 2019 Sep; 8(10):. PubMed ID: 31557902
[TBL] [Abstract][Full Text] [Related]
23. FGFR signaling maintains a drug persistent cell population following epithelial-mesenchymal transition.
Brown WS; Akhand SS; Wendt MK
Oncotarget; 2016 Dec; 7(50):83424-83436. PubMed ID: 27825137
[TBL] [Abstract][Full Text] [Related]
24. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
25. Epithelial-to-mesenchymal transition and cancer stem(-like) cells in head and neck squamous cell carcinoma.
Chen C; Zimmermann M; Tinhofer I; Kaufmann AM; Albers AE
Cancer Lett; 2013 Sep; 338(1):47-56. PubMed ID: 22771535
[TBL] [Abstract][Full Text] [Related]
26. Role of JAK/STAT3 Signaling in the Regulation of Metastasis, the Transition of Cancer Stem Cells, and Chemoresistance of Cancer by Epithelial-Mesenchymal Transition.
Jin W
Cells; 2020 Jan; 9(1):. PubMed ID: 31952344
[TBL] [Abstract][Full Text] [Related]
27. Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells.
Espinoza I; Miele L
Cancer Lett; 2013 Nov; 341(1):41-5. PubMed ID: 23973264
[TBL] [Abstract][Full Text] [Related]
28. The therapeutic potential of targeting the epithelial-mesenchymal transition in cancer.
Ginnebaugh KR; Ahmad A; Sarkar FH
Expert Opin Ther Targets; 2014 Jul; 18(7):731-45. PubMed ID: 24758643
[TBL] [Abstract][Full Text] [Related]
29. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin β3/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery.
Jin H; He Y; Zhao P; Hu Y; Tao J; Chen J; Huang Y
Theranostics; 2019; 9(1):265-278. PubMed ID: 30662566
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms promoting physiological cells progression into tumorigenesis.
Korbut E; Ptak-Belowska A; Brzozowski T
J Physiol Pharmacol; 2012 Dec; 63(6):565-70. PubMed ID: 23388471
[TBL] [Abstract][Full Text] [Related]
31. Tumor-associated macrophages and epithelial-mesenchymal transition in cancer: Nanotechnology comes into view.
Vakili-Ghartavol R; Mombeiny R; Salmaninejad A; Sorkhabadi SMR; Faridi-Majidi R; Jaafari MR; Mirzaei H
J Cell Physiol; 2018 Dec; 233(12):9223-9236. PubMed ID: 30078227
[TBL] [Abstract][Full Text] [Related]
32. Roles of Dietary Phytoestrogens on the Regulation of Epithelial-Mesenchymal Transition in Diverse Cancer Metastasis.
Lee GA; Hwang KA; Choi KC
Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27231938
[TBL] [Abstract][Full Text] [Related]
33. Targeting the Epithelial-to-Mesenchymal Transition in Cancer Stem Cells for a Better Clinical Outcome of Glioma.
Lu YB; Sun TJ; Chen YT; Cai ZY; Zhao JY; Miao F; Yang YN; Wang SX
Technol Cancer Res Treat; 2020; 19():1533033820948053. PubMed ID: 33089751
[TBL] [Abstract][Full Text] [Related]
34. Epithelial-mesenchymal transition and drug resistance: role, molecular mechanisms, and therapeutic strategies.
Sui H; Zhu L; Deng W; Li Q
Oncol Res Treat; 2014; 37(10):584-9. PubMed ID: 25342509
[TBL] [Abstract][Full Text] [Related]
35. Semaphorins as Regulators of Phenotypic Plasticity and Functional Reprogramming of Cancer Cells.
Gurrapu S; Tamagnone L
Trends Mol Med; 2019 Apr; 25(4):303-314. PubMed ID: 30824197
[TBL] [Abstract][Full Text] [Related]
36. The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links.
Liu X; Fan D
Curr Pharm Des; 2015; 21(10):1279-91. PubMed ID: 25506898
[TBL] [Abstract][Full Text] [Related]
37. Stem cell programs in cancer initiation, progression, and therapy resistance.
Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
[TBL] [Abstract][Full Text] [Related]
38. Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer.
Sun L; Burnett J; Gasparyan M; Xu F; Jiang H; Lin CC; Myers I; Korkaya H; Liu Y; Connarn J; He H; Zhang N; Wicha MS; Sun D
Oncotarget; 2016 Aug; 7(32):51408-51422. PubMed ID: 27285982
[TBL] [Abstract][Full Text] [Related]
39. EHMT1/EHMT2 in EMT, cancer stemness and drug resistance: emerging evidence and mechanisms.
Nachiyappan A; Gupta N; Taneja R
FEBS J; 2022 Mar; 289(5):1329-1351. PubMed ID: 34954891
[TBL] [Abstract][Full Text] [Related]
40. Epithelial-mesenchymal transition and drug resistance in breast cancer (Review).
Huang J; Li H; Ren G
Int J Oncol; 2015 Sep; 47(3):840-8. PubMed ID: 26202679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
